Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Benitec Biopharma Inc.NASDAQ: BNTC
Stock-Based Compensation · Q3 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q3 FY2026 stock-based compensation was $0, compared with $2.6M a year earlier. Trailing-twelve-month stock-based compensation was $12.56M. Over 3 fiscal years it compounded at +171.6% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $3.14M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 17.43M USD
- Year-over-year change
- +1999.5%
- 4-year CAGR
- +129.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 17.43M | +1999.5% |
| FY2024 | 2024-06-30 | 830K | +83.6% |
| FY2023 | 2023-06-30 | 452K | -48.0% |
| FY2022 | 2022-06-30 | 870K | +37.2% |
| FY2021 | 2021-06-30 | 634K | — |
Stock-Based Compensation vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's LTM Mar 2026 stock-based compensation of $12.56M is the 3rd largest of the 10 companies compared; the peer median is $8.22M.
- Its year-over-year change of +183.6% is the highest of 10, against a peer median of -8.3%.
- Over three fiscal years its annual growth of +171.6% compares with a peer median of +3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $18.73M | +52.9% | +30.9% | — | |
| LTM Mar 2026 | $15.14M | -5.7% | +6.3% | 16.3% | |
| LTM Mar 2026 | $12.56M | +183.6% | +171.6% | — | |
| LTM Mar 2026 | $10.98M | +14.3% | -1.3% | 592.7% | |
| LTM Mar 2026 | $9.22M | +22.1% | -9.9% | 206.5% | |
| FY2025 | $8.22M | -64.0% | -17.6% | 176.5% | |
| LTM Mar 2026 | $4.71M | -8.3% | +3.5% | 31.8% | |
| LTM Mar 2026 | $3.92M | -16.2% | +37.0% | 10.8% | |
| LTM Mar 2026 | $3.41M | -69.9% | +124.6% | — | |
| LTM Mar 2026 | $1.88M | -18.8% | -16.7% | — | |
| Peer median (excluding BNTC) | $8.22M | -8.3% | +3.5% | 104.2% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (13.88M) | (18.21M) | (19.56M) | (21.75M) | (37.92M) |
| Depreciation & Amortization | 424K | 392K | 381K | 343K | 396K |
| Deferred Income Tax | 0 | 0 | (714K) | 0 | 0 |
| Stock-Based Compensation | 634K | 870K | 452K | 830K | 17.43M |
| Change in Working Capital | 8K | 1.04M | 714K | 1.17M | (2.73M) |
| Accounts Receivables | 28K | 1K | (50K) | (176K) | 197K |
| Inventory | (83K) | (1.09M) | (1.31M) | 0 | 0 |
| Accounts Payables | 55K | 1.09M | 1.36M | 0 | (2.38M) |
| Other Working Capital | 8K | 1.04M | 714K | 1.35M | (548K) |
| Other Non-Cash Items | (16K) | 10K | 717K | 1K | (764K) |
| Operating Cash Flow | (12.83M) | (15.9M) | (18.01M) | (19.4M) | (23.59M) |
| Capital Expenditures | (221K) | (13K) | (1K) | (179K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (221K) | (13K) | (1K) | (179K) | (18K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 25.75M | 0 | 17.88M | 70.88M | 70.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.23M) | 0 | (1.87M) | (2.85M) | 0 |
| Financing Cash Flow | 22.52M | 0 | 16.02M | 68.03M | 70.49M |
| Effect of Forex Changes | 499K | 204K | 412K | (8K) | 49K |
| Net Change in Cash | 9.97M | (15.71M) | (1.59M) | 48.44M | 46.93M |
| Free Cash Flow | (13.05M) | (15.91M) | (18.01M) | (19.58M) | (23.61M) |
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.